ClinicalTrials.gg
Active, not recruitingNCT05786573Updated Jun 25, 2025

A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)

A Phase 3 interventional study of Obexelimab and Obexelimab in Warm Autoimmune Hemolytic Anemia, sponsored by Zenas BioPharma (USA), LLC. Active, not recruiting at 7 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-25.

Sponsored by Zenas BioPharma (USA), LLC · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
134
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Anemia, Hemolytic, Autoimmune with a site in Spain — 2 open to participants now, 7 under way, 5 of them phase 3. Anemia, Hemolytic, Autoimmune · Spain.

Planned enrollment
Largest of 14
134 · median 36
Started
2023
with 1 other
Phase 3
9 of 15
2 open now
Registered
14th of 15
by date

Among the 15 studies in Anemia, Hemolytic, Autoimmune with a site in Spain, this one has the largest planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2023, is one of 9 in phase 3, and was the 14th registered.

Anemia, Hemolytic, Autoimmune

103 studies on the registry are indexed under Anemia, Hemolytic, Autoimmune; 39 are open to participants now.

Browse Anemia, Hemolytic, Autoimmune studies →

Open to participants now

2 of the 15 studies in Anemia, Hemolytic, Autoimmune with a site in Spain are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 24 Anemia, Hemolytic, Autoimmune studies recruiting now, 12 (50%) set no upper age limit and 10 (42%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Anemia, Hemolytic, Autoimmune with a site in Spain, or all of them as a file.
02

Study summary

This study aims to examine the efficacy and safety of obexelimab in participants with Warm Autoimmune Hemolytic Anemia (wAIHA).

Read the detailed description

This study consists of a 6-month open label Safety and Dose Confirmation Run-in Period (SRP), 6-month Randomized Control Period (RCP), and an additional 1-year open-label extension (OLE) period. To enter the Screening Period (Day -28 to Day -1) in the SRP or RCP, patients must have a clinical diagnosis of primary or secondary wAIHA due to an underlying autoimmune disorder, have failed at least 1 prior wAIHA treatment regimen, and have a Hgb level of ≥ 7 to \< 10 g/dL with at least one sign or symptom of anemia. For the SRP only, patients with secondary wAIHA due to underlying lymphoproliferative disease may be eligible if they are receiving stable treatment.

All patients in the SRP or RCP are allowed to continue up to 2 failed wAIHA therapies throughout the 24-week study. On Day 1 of the SRP, patients receive obexelimab administered as subcutaneous (SC) injections. On Day 1 of the RCP, patients will be randomized in a ratio of 1:1 to receive either obexelimab or placebo administered as subcutaneous (SC) injections. Patients must return to the study site for the first 5 weeks and then every 2 weeks thereafter. Patients will undergo assessments for efficacy, safety, PK, PD, and immunogenicity during the 24-week SRP or RCP.

Following the 24-week SRP or RCP, patients will have the opportunity to receive obexelimab for up to 52 weeks in the Open Label Extension (OLE) Period.

Including screening and follow-up, the maximum duration of participation in this study for an individual patient is 81 weeks (i.e., 28-day screening, 24-week SRP or RCP, 52-week OLE, and an 8-week follow-up).

03

Conditions studied

  • Warm Autoimmune Hemolytic Anemia

Keywords

  • Warm Autoimmune Hemolytic Anemia
  • wAIHA
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females, ≥ 18 years of age
  2. Clinically diagnosed with wAIHA for at least 3 months and currently receiving treatment for wAIHA or have previously received treatment for wAIHA.
  3. Diagnosis of primary or secondary wAIHA documented by a positive direct antiglobulin test specific for anti-IgG or anti-IgA.
  4. Failed at least 1 prior wAIHA treatment regimen.
  5. At least one sign or symptom of anemia as assessed by the investigator at screening.
  6. Other inclusion criteria apply.

Exclusion criteria

Exclusion Criteria:

  1. Have cold antibody AIHA, cold agglutinin syndrome, mixed type (i.e., warm, and cold) AIHA, or paroxysmal cold hemoglobinuria.
  2. Have any other associated cause of hereditary or acquired hemolytic anemia.
  3. For the RCP only, patients with secondary wAIHA not due to disorders, including LPDs.
  4. Received a transfusion within 2 weeks prior to randomization.
  5. Use of B cell-depleting, B cell-targeted, or other biologic immunomodulatory agents within the 6 months prior to randomization.
  6. Received IV Ig or epoetin alfa within 6 weeks prior to randomization.
  7. Receiving more than 2 concomitant medications for the treatment of wAIHA.
  8. Other exclusion criteria apply.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
134 participants (estimated)

Study arms

  • Experimental
    Safety and Dose Confirmation Run-in Period (SRP): Obexelimab

    Obexelimab will be administered as an SC injection for 24 weeks.

    Drug: Obexelimab

  • Experimental
    Randomized Control Period (RCP): Obexelimab

    Obexelimab will be administered as an SC injection for 24 weeks.

    Drug: Obexelimab

  • Placebo comparator
    Randomized Control Period (RCP): Placebo

    Placebo will be administered as an SC injection for 24 weeks

    Other: Placebo

Interventions

  • Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcγRIIb, resulting in down regulation of B cell activity.

  • Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcγRIIb, resulting in down regulation of B cell activity.

  • OtherPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Safety and Dose Confirmation Run-in Period (SRP)

    Proportion of participants with hemoglobin (Hgb) ≥ 10 g/dL and ≥ 2 g/dL increase from Baseline with no use of blood transfusion or glucocorticoid (GC) rescue therapy.

    Time frame: 24 weeks

  2. Randomized Control Period (RCP)

    Proportion of participants who achieve a durable Hgb response (defined as Hgb ≥ 10 g/dL and ≥ 2 g/dL increase from Baseline on at least 3 of 4 consecutive available visits), at the earliest on or after Week 12, with no use of blood transfusion or GC rescue therapy prior to attaining durable response through Week 24.

    Time frame: 24 weeks

07

Study locations

7 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2023 (actual). Primary completion is estimated for Jun 2026, 33 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2023
First posted
Mar 27, 2023
StartActual
Sep 25, 2023
Primary completionEst.
Jun 30, 2026
CompletionEst.
Aug 31, 2026
Last update
Jun 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05786573
Lead sponsor
Zenas BioPharma (USA), LLC
Responsible party
Sponsor
First posted
Mar 27, 2023
Start date
Sep 25, 2023
Primary completion
Jun 30, 2026 (estimated)
Completion
Aug 31, 2026 (estimated)
Last update
Jun 25, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Obexelimab

Start the discussion